F M Investments LLC Has $2.50 Million Stock Position in Pfizer Inc. (NYSE:PFE)

F M Investments LLC boosted its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 15.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 94,051 shares of the biopharmaceutical company's stock after purchasing an additional 12,895 shares during the period. F M Investments LLC's holdings in Pfizer were worth $2,495,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of PFE. Vanguard Group Inc. boosted its position in shares of Pfizer by 0.4% in the 4th quarter. Vanguard Group Inc. now owns 518,535,151 shares of the biopharmaceutical company's stock worth $13,756,738,000 after purchasing an additional 2,285,276 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in Pfizer by 19.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company's stock worth $4,124,330,000 after buying an additional 25,315,159 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Pfizer by 2.5% during the 4th quarter. Geode Capital Management LLC now owns 120,589,782 shares of the biopharmaceutical company's stock worth $3,190,131,000 after buying an additional 2,923,537 shares during the period. Norges Bank bought a new stake in shares of Pfizer in the 4th quarter valued at about $2,328,986,000. Finally, Massachusetts Financial Services Co. MA raised its position in shares of Pfizer by 7.5% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 76,502,238 shares of the biopharmaceutical company's stock valued at $2,029,604,000 after acquiring an additional 5,350,381 shares during the period. 68.36% of the stock is currently owned by institutional investors.

Remove Ads

Pfizer Stock Performance

Shares of PFE traded up $0.20 during mid-day trading on Monday, hitting $22.11. 50,694,569 shares of the company's stock were exchanged, compared to its average volume of 40,315,662. The firm has a market cap of $125.40 billion, a price-to-earnings ratio of 15.68, a price-to-earnings-growth ratio of 0.64 and a beta of 0.67. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $31.54. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The stock's 50-day simple moving average is $25.25 and its 200-day simple moving average is $26.38.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating analysts' consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. During the same period in the prior year, the company posted $0.10 EPS. The company's revenue was up 24.7% compared to the same quarter last year. On average, equities research analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Insider Buying and Selling at Pfizer

In other news, Director Ronald E. Blaylock purchased 19,457 shares of Pfizer stock in a transaction that occurred on Thursday, February 13th. The shares were acquired at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the transaction, the director now owns 27,707 shares of the company's stock, valued at approximately $710,684.55. The trade was a 235.84 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Insiders own 0.06% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages have commented on PFE. Truist Financial lowered their target price on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating for the company in a research note on Wednesday, December 18th. UBS Group lowered their target price on Pfizer from $28.00 to $24.00 and set a "neutral" rating for the company in a report on Tuesday, April 8th. Guggenheim reaffirmed a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. Hsbc Global Res raised Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. Finally, Citigroup reiterated a "neutral" rating on shares of Pfizer in a report on Thursday, March 27th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have given a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $31.07.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.